FrieslandCampina Ingredients has announced that its Hyvital® Whey HA 300, a protein hydrolysate specifically developed for infant and follow-on formulas, has received approval for use across the European Union. This approval follows a rigorous scientific evaluation under the EU’s latest regulations, ensuring compliance with the highest safety and suitability standards.
Although Hyvital® Whey HA 300 has been on the market since 2010, changes in EU regulations in February 2022 required a new safety and suitability evaluation for protein hydrolysates used in standard infant nutrition.
After having successfully passed this scientific evaluation, and subsequent approval by the European commission, Hyvital® Whey HA 300 is now one of only a few milk hydrolysate ingredients that is included in the Commission Delegated Regulation (EU) 2016/127 – the final step required for its use in infant and follow-on formulas sold throughout the EU.
Said Jouke Veldman, Marketing Director of Early Life Nutrition, FrieslandCampina Ingredients: “We’re absolutely thrilled that Hyvital® Whey HA 300 has received this approval. This decision not only broadens the options available for developing formulas for infants, but also reinforces our commitment to meeting the highest industry standards. I would like to extend my gratitude to our dedicated R&D teams in Ingredients, Global Nutrition and Scientific & Regulatory Affairs. Their hard work and expertise were instrumental in securing this approval and achieving this important milestone. Our customers can trust that we continue to prioritise safety, quality, and innovation.”
The inclusion of Hyvital® Whey HA 300 in the EU legislation further strengthens FrieslandCampina Ingredients’ position as a trusted leader in early life nutrition, with a focus on delivering high-quality solutions for infants. For more visit frieslandcampinaingredients.com
